Hjem › Brystkreft › Alabama › Birmingham
Kliniske studier for Brystkreft i Birmingham, AL
24 studier for Brystkreft søker deltakere på steder i og rundt Birmingham (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
RekruttererFase 2
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
RekruttererFase 3
- Central Alabama Research, Birmingham
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
RekruttererFase 2
- Alabama Oncology, Birmingham
PRE-ISPY Phase I/II Oncology Platform Program
RekruttererFase 1/2
- The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham
Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer
RekruttererFase 2
- University of Alabama at Birmingham, Birmingham
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
RekruttererFase 1
- University of Alabama At Birmingham Hospital, Birmingham
Improved Successful Retrieval Rate of HydroMARK Plus Breast Biopsy Site Marker in Comparison to HydroMARK as Well as Improved Surgeon Satisfaction
Rekrutterer
- The Kirklin Clinic, Birmingham
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
RekruttererFase 1/2
- University of Alabama at Birmingham, Birmingham
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
RekruttererFase 2
- University of Alabama at Birmingham, Birmingham
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
RekruttererFrivillige helsepersonell ønskes velkommen
- University of Alabama at Birmingham, Birmingham
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RekruttererFase 1
- University of Alabama Birmingham, Birmingham
Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
RekruttererObservasjonsstudie
- Birmingham Hematology Associates, Birmingham
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
RekruttererFase 2
- University of Alabama, Birmingham
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
RekruttererFrivillige helsepersonell ønskes velkommen
- University of Alabama, Birmingham, Birmingham
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RekruttererFase 1
- Uni of Alabama at Birmingham, Birmingham
Promoting Resilience in Women With Breast Cancer (PRISM -MBC)
Rekrutterer
- The University of Alabama, Birmingham
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RekruttererFase 2
- University of Alabama at Birmingham, Birmingham
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Rekrutterer
- University of Alabama at Birmingham, Birmingham
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
RekruttererFase 2
- University of Alabama at Birmingham, Birmingham
Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
RekruttererTidlig fase 1
- The Kirklin Clinic, Birmingham
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
RekruttererFase 2
- University of Alabama Birmingham, Birmingham
Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
Rekrutterer
- The University of Alabama at Birmingham, Birmingham
RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)
Rekrutterer
- University of Alabama at Birmingham (UAB) Hazelrig-Salter Radiation Oncology Center (HSROC), Birmingham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, Birmingham
Brystkreft-studier i andre byer
- New York City, NY136 studier
- Houston, TX126 studier
- Boston, MA112 studier
- Nashville, TN81 studier
- Los Angeles, CA73 studier
- Edison, NJ68 studier
- St. Louis, MO64 studier
- Queens, NY64 studier
- Durham, NC64 studier
- Chicago, IL59 studier
- Philadelphia, PA56 studier
- Dallas, TX55 studier
Andre studier i Birmingham
- Kreft (alle typer)31 studier
- Eggstokkreft23 studier
- Fedme23 studier
- Ikke-småcellet lungekreft22 studier
- Akut myelogen leukemi21 studier
- Multipelt myelom18 studier
- KOLS17 studier
- Kardiovaskulær sykdom17 studier
- Type 2-diabetes16 studier
- Endometriekreft16 studier
- Overvekt16 studier
- Cystisk fibrose16 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.